| Product Name: | ETIZOLAM | | Synonyms: | 4-c)thieno(2,3-e)(1,4)-diazepine,6-(o-chlorophenyl)-8-ethyl-1-4h-s-triazolo(;6-(o-chlorophenyl)-8-ethyl-1-methyl-4h-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-d;6-(o-chlorphenyl)-8-aethyl-1-methyl-4h-s-triazolo(3,4-c)thieno(2,3-e)(1,4)di;6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine,4-(2-chlorophenyl)-2-et;8-ethyl-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(3,4c)thieno(2,3e)-1,4-diaz;ahr3219;depas;hyl-9-methyl- | | CAS: | 40054-69-1 | | MF: | C17H15ClN4S | | MW: | 342.85 | | EINECS: | 662-368-4 | | Product Categories: | pharmaceutical intermediate and medicine grade;pharmaceutical intermediate;Inhibitors;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;intermediate | | Mol File: | 40054-69-1.mol |  |
| | ETIZOLAM Chemical Properties |
| Melting point | 147-148℃ | | Boiling point | 264.5°C (rough estimate) | | density | 1.43 | | refractive index | 1.6100 (estimate) | | Fp | 9°C | | storage temp. | -20°C | | solubility | DMF: 5 mg/ml; DMSO: 5 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml | | form | A neat solid | | pka | 2.37±0.40(Predicted) | | CAS DataBase Reference | 40054-69-1 |
| Hazard Codes | F,T | | Risk Statements | 11-23/24/25-39/23/24/25 | | Safety Statements | 7-16-36/37-45 | | RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution | | WGK Germany | 1 | | Toxicity | LD50 in male, female rats, male, female mice (mg/kg): 3619, 3509, 4358, 4258 orally; 865, 825, 830, 783 i.p.; >5000 s.c. (Tsumagari) |
| | ETIZOLAM Usage And Synthesis |
| Description | Etizolam is a benzodiazepine analog used for the short-term treatment of insomnia, anxiety or panic attacks. It has amnesic, anxiolytic, anticonvulsant, and hypnotic, sedative and skeletal muscle relaxant properties. It acts on the benzodiazepine site of the GABA-A receptor as an agonist to increase inhibitory GABAergic transmission throughout the central nervous system.
| | References | https://www.drugbank.ca/drugs/DB09166
https://en.wikipedia.org/wiki/Etizolam
Casacchia, Massimo, F. Bolino, and U. Ecari. "Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo."Current Medical Research & Opinion 12.4(2008):215-223.
Savoldi, F, G. Somenzini, and U. Ecari. "Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study."Current Medical Research & Opinion 12.3(1990):185.
Hirashima, Y, et al. "Etizolam, an anti-anxiety agent, attenuates recurrence of chronic subdural hematoma--evaluation by computed tomography." Neurologia medico-chirurgica 42.2(2002):53-55.
| | Description | Etizolam is a potent thienodiazepine anxiolytic closely related to brotizolam.
Pharmacologically, however, its profile most resembles that of diazepam. | | Originator | Yoshitomi (Japan) | | Uses | Etilozam is a a thienodiazepine benzodiazepine derivative, and has amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. Etizolam is an anxiolytic related to
that of the classic benzodiazepines. Etizolam has effect on monoamine metabolism in brain.
Etilozam can be used for the short-term treatment of insomnia, anxiety or panic attacks. | | Uses | Nasal Dilator | | Definition | ChEBI: Etizolam is an organic molecular entity. | | Brand name | DEPAS |
| | ETIZOLAM Preparation Products And Raw materials |
|